Research Paper Volume 12, Issue 5 pp 4547—4557

Figure 4. ARV-825 oral administration inhibits TPC-1 xenograft tumor growth in SCID mice. SCID mice bearing TPC-1 xenografts (100 mm³ at “Day-0”) were treated with ARV-825 (daily gavage, 5 or 25 mg/kg body weight, for 21 consecutive days), the tumor volumes (A) and the mice body weights (D) were recorded every seven days (recording five rounds). The estimated daily tumor growth (in mm³ per day) was calculated (B). At “Day-35” tumors of all three groups were isolated and weighted (C). At treatment “Day-7” and “Day-14”, one tumor of each group was isolated, with fresh tumor tissue lysates analyzed by Western blotting for listed proteins (E and F). Expression of listed proteins was quantified and normalized to Erk1/2 (E and F). Vehicle stands for 10% DMSO, 40% PEG300, 5% Tween-80 plus 45% saline. For each group, n= 10 mice. ***p < 0.001 vs. “Vehicle” group.